16. EXPERIMENTAL STUDY PROCEDURES (DC + XALT THERAPY) 16.1 DC Vaccination Following myeloablative (Group A) and NMA chemotherapy (Group B) , patients will receive intravenous TTRNA -xALT at 3x107cells/kg and intradermal TTRNA -DCs as vaccine #1. Peripheral blood will be drawn prior to non- mobilized leukapheresis , prior to immunotherapy, 1 day post Vaccine #1, 4 (+/- 1) days post Vaccine #1, weekly post Vaccine #1 for six weeks , and bimonthly , if feasible, until progression for T cell kinetics. Blood will be processed in accordance with SOP -UFBTIP -126. DCs will be given intradermally and divided equally to both inguinal regions in accordance with SOP -UFBTIP -128. Vaccines #2 and #3 will occur at 2 week intervals following the first dose. Each immunization will be divided equally to both inguinal regions. A total volume of 200 µL per side will be delivered intradermally after preparation of skin with EMLA anesthetic cream. Details of the procedur e will be recorded on SDW -UFBTIP -002.